New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rifampicin 600mg - tablet - 600 mg - active: rifampicin 600mg excipient: acacia calcium stearate carmellose sodium carnauba wax colloidal silicon dioxide colophony erythrosine ethanol gelatin hard paraffin kaolin lactose monohydrate magnesium carbonate magnesium stearate maize starch microcrystalline cellulose povidone purified talc purified water sodium laurilsulfate sucrose titanium dioxide white beeswax - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - oxaliplatin 5 mg/ml - concentrate for infusion - 5 mg/ml - active: oxaliplatin 5 mg/ml excipient: water for injection - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - buserelin acetate 1.05 mg/ml equivalent to 1 mg/ml buscerelin - solution for injection - 1 mg/ml - active: buserelin acetate 1.05 mg/ml equivalent to 1 mg/ml buscerelin excipient: benzyl alcohol monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide water for injection - for the treatment of endometriosis not primarily requiring surgical treatment. pituitary desensitisation in preparation for ovulation induction regimens using gonadotrophins.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - atovaquone 250mg; proguanil hydrochloride 100mg - film coated tablet - active: atovaquone 250mg proguanil hydrochloride 100mg excipient: colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry brown 03c86943 poloxamer sodium starch glycolate tolpovidone i 131 - promozio (250mg atovaquone/100mg proguanil hydrochloride) is indicated for: · prophylaxis of plasmodium falciparum malaria in adults · treatment of plasmodium falciparum malaria in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sevelamer carbonate 800mg; sevelamer carbonate 800mg - film coated tablet - 800 mg - active: sevelamer carbonate 800mg excipient: isopropyl alcohol microcrystalline cellulose opacode opadry clear propylene glycol sodium chloride zinc stearate active: sevelamer carbonate 800mg excipient: acetylated monoglycerides hypromellose e-15 hypromellose e-5 isopropyl alcohol microcrystalline cellulose opacode propylene glycol sodium chloride zinc stearate - renvela is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sevelamer carbonate 1600mg - powder for oral suspension - 1.6 g - active: sevelamer carbonate 1600mg excipient: 'natural and artificial citrus cream' proprietary flavouring iron oxide yellow propylene glycol alginate sodium chloride sucralose - renvela is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sevelamer carbonate 2400mg - powder for oral suspension - 2.4 g - active: sevelamer carbonate 2400mg excipient: 'natural and artificial citrus cream' proprietary flavouring iron oxide yellow propylene glycol alginate sodium chloride sucralose - renvela is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 100 mg/ml;   - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml   excipient: caramel hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water sweetener gesweet 01002023 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.